These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7793140)

  • 1. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development.
    Crowe JE
    Vaccine; 1995 Mar; 13(4):415-21. PubMed ID: 7793140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.
    Murphy BR; Collins PL
    Bull World Health Organ; 1997; 75(4):307-13. PubMed ID: 9342889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.
    Tang RS; Schickli JH; MacPhail M; Fernandes F; Bicha L; Spaete J; Fouchier RA; Osterhaus AD; Spaete R; Haller AA
    J Virol; 2003 Oct; 77(20):10819-28. PubMed ID: 14512532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.
    Murphy BR; Hall SL; Kulkarni AB; Crowe JE; Collins PL; Connors M; Karron RA; Chanock RM
    Virus Res; 1994 Apr; 32(1):13-36. PubMed ID: 8030364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.
    Murphy BR; Prince GA; Collins PL; Van Wyke Coelingh K; Olmsted RA; Spriggs MK; Parrott RH; Kim HW; Brandt CD; Chanock RM
    Virus Res; 1988 Aug; 11(1):1-15. PubMed ID: 2845680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells.
    Nelson CL; Tang RS; Stillman EA
    Vaccine; 2013 Aug; 31(36):3756-62. PubMed ID: 23623857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of vaccines for parainfluenza virus infections.
    Sato M; Wright PF
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S123-5. PubMed ID: 18820572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003.
    Schmidt AC; Johnson TR; Openshaw PJ; Braciale TJ; Falsey AR; Anderson LJ; Wertz GW; Groothuis JR; Prince GA; Melero JA; Graham BS
    Virus Res; 2004 Nov; 106(1):1-13. PubMed ID: 15522442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.
    Bernstein DI; Malkin E; Abughali N; Falloon J; Yi T; Dubovsky F;
    Pediatr Infect Dis J; 2012 Feb; 31(2):109-14. PubMed ID: 21926667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
    Belshe RB; Newman FK; Anderson EL; Wright PF; Karron RA; Tollefson S; Henderson FW; Meissner HC; Madhi S; Roberton D; Marshall H; Loh R; Sly P; Murphy B; Tatem JM; Randolph V; Hackell J; Gruber W; Tsai TF
    J Infect Dis; 2004 Dec; 190(12):2096-103. PubMed ID: 15551207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective and disease-enhancing immune responses to respiratory syncytial virus.
    Anderson LJ; Heilman CA
    J Infect Dis; 1995 Jan; 171(1):1-7. PubMed ID: 7798649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
    Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.
    Tang RS; MacPhail M; Schickli JH; Kaur J; Robinson CL; Lawlor HA; Guzzetta JM; Spaete RR; Haller AA
    J Virol; 2004 Oct; 78(20):11198-207. PubMed ID: 15452239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections.
    Hurwitz JL
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S126-8. PubMed ID: 18820573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials.
    Lee MS; Walker RE; Mendelman PM
    Hum Vaccin; 2005; 1(1):6-11. PubMed ID: 17038832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.